The effects of other antidiabetic drugs, such as thiazolidinediones, DPP-4i, glucagon-like peptide-1 receptor agonist (GLP-1RA), or sodium-glucose cotransporter 2 (SGLT2) inhibitors on the risk of developing DR, remain uncertain in patients with T2DM [13]. Here, SLC5A2 is linked to type 2 diabetes mellitus.